CMPS · COMPASS Pathways Plc · Stock research

Price basis: last completed daily close $13.54 (2026-08-07). 52-week high $15.07 (-10.2%). 3-month return +36.6%. RSI(14) 67.7.

CMPS — COMPASS Pathways plc

Current Thesis

The clinical binary resolved on 2026-07-07 when COMP006 delivered positive 26-week Phase 3 data in treatment-resistant depression. The 2026-08-05 Q2 print and the 2026-08-06 VA collaboration extended the story without adding a dated near-term event, and the same-day filing of a mixed shelf prospectus put issuance capacity back on file while the stock sits 10.2% under its 52-week high after a 36.6% three-month run.

Bullish and bearish views on COMPASS Pathways Plc

The model's bull view on COMPASS Pathways Plc (CMPS), in brief: Cash and cash equivalents $433.3M at 2026-06-30, with the company stating the position is sufficient into 2028 — i.e. through the guided launch window (Q2 2026 release, 2026-08-05). The bear view: A mixed shelf prospectus was filed 2026-08-05, terms undisclosed, the same day as the runway commentary. Both cases follow in full.

Bull Case

• Cash and cash equivalents $433.3M at 2026-06-30, with the company stating the position is sufficient into 2028 — i.e. through the guided launch window (Q2 2026 release, 2026-08-05).
• Rolling NDA submission underway with all modules targeted for Q4 2026; COMP360 launch guided to H1 2027 subject to FDA approval and DEA rescheduling (2026-08-05).
• Company states roughly 90% of the US patient population lives in states that intend to reschedule within 30 days of federal DEA action (2026-08-05) — the state-lag problem that normally follows a federal schedule change is framed as small.
• 2026-08-06: VA collaboration on PIVOT, a multi-site double-blind randomized trial in veterans with TRD with or without PTSD, comparing two COMP360 doses with an optional second open-label administration at week four, MADRS primary. Compass donates study drug, so the government sponsor carries trial cost.
• Adjusted Q2 EPS $(0.36) versus $(0.40) consensus (2026-08-05), the adjusted figure excluding warrant fair-value movement.
• Target band sits above the tape: B. Riley raised to $22 and Morgan Stanley to $18 (both 2026-08-06), RBC $21 (2026-08-06), with BTIG $25 (2026-07-07) and Evercore/Stifel $21 (2026-07-08) from the readout cluster.

Bear Case

• A mixed shelf prospectus was filed 2026-08-05, terms undisclosed, the same day as the runway commentary. The precedent is recent: the company announced pricing of a $150.0M ADS offering on 2026-02-18. Registered capacity is not a raise, but it is the mechanism.
• GAAP Q2 net loss $253.8M, $(1.88) per share against a $(0.37) estimate, driven by a $205.6M non-cash change in warrant fair value. That liability is remeasured upward as the share price rises, so headline GAAP losses widen precisely when the equity works.
• Nothing is scheduled inside the next 30 days. NDA completion is a Q4 2026 item; approval and DEA action are 2027 events. A +36.6% three-month move has to hold on flow alone.
• Sell-side dispersion is unusually wide and the last actions cut in both directions: Wells Fargo initiated Equal-Weight at $13 on 2026-07-27, level with the tape, while HC Wainwright lowered its target from $70 to $65 on 2026-08-07 and RBC lowered to $21 on 2026-08-06.
• Pre-revenue with a commercial organization already hired ahead of approval: H1 2026 R&D $55.7M and G&A $39.6M, on 135,722,306 ordinary shares at 2026-06-30.
• Label and REMS negotiation, plus the functional-unblinding critique of psychedelic trial design, remain open items the two positive Phase 3s do not settle.

Setup & Price Structure

• $13.54 close on 2026-08-07, 10.2% below the $15.07 52-week high, RSI(14) 67.7 — extended but short of the >75 readings that usually mark exhaustion in this name.
• The July note framed the COMP006 gap origin near $9–10, roughly where the pre-readout low-$8s tape had been repriced. Price has carried several points clear of that shelf, so the $10 line that anchored the July frame is stale as a working risk level.
• No base has formed above the 2026-08-05 print. Continuation requires holding the post-print range and clearing $15.07 on expanding volume; the alternative path is a drift back into the $11s over the eight-to-ten weeks before the Q4 NDA completion becomes tradeable news.
• Crowding observables, stated as observed: nine covering desks issued targets between 2026-07-07 and 2026-08-07; a mixed shelf went on file 2026-08-05; the earnings date is behind rather than ahead, removing the usual pre-print compression; and two of the four most recent target actions were reductions.

Catalyst Calendar (next 30 days)

• No confirmed company-dated catalyst falls between 2026-08-08 and 2026-09-07. The next hard dates sit outside the window.
• ~2026-11-04 (est.): Q3 2026 results — no date announced; Q2 landed 2026-08-05.
• H1 2027 (guided): US COMP360 launch, conditional on FDA approval and DEA rescheduling.

Elapsed catalysts

• ~Q4 2026 (company-guided 2026-08-05): completion of the rolling NDA submission, all modules. (passed 4d ago)
• Undated: DEA scheduling action on psilocybin; first-patient-in for the VA PIVOT trial announced 2026-08-06. (passed 3d ago)

What Would Change Our Mind

The cleanest break would be a priced equity offering drawn off the 2026-08-05 shelf at a discount to the tape — that would convert the "funded into 2028" language into an old statement and reset the share count above 135.7M. Second, the Q4 2026 rolling-NDA completion slipping into 2027 would push the H1 2027 launch guide with it and remove the only company-controlled milestone left this year. Third, an FDA refuse-to-file or a clinical hold would take the regulatory leg off the table entirely. On price, a weekly close below $11.50 gives back the post-Q2 range and more than half the July readout leg, which would say the re-rating has been sold rather than consolidated. A run through $15.07 on volume with the Q4 filing on track argues the opposite.

Correlation Notes

• The psychedelic-CNS complex (ATAI, MNMD, CYBN) trades together on policy headlines; the 2026-04-24 cluster — FDA rolling-review request, the Commissioner's National Priority Voucher, and the FDA statement following the executive order on serious mental illness — moved the group, not just CMPS.
• DEA scheduling policy is a shared factor with cannabis rescheduling names, which is why the theme tag persists even though the business has no cannabis exposure.
• As a pre-revenue clinical-stage issuer, the name carries no macro read-through; its sensitivity runs to biotech equity-issuance conditions and to single-headline risk, which historically produces 15–25% single-session moves in both directions.